Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 247

Results For "NDA"

4483 News Found

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
News | July 03, 2023

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025


AstraZeneca announces US$400 million investment in reforestation and biodiversity
News | June 28, 2023

AstraZeneca announces US$400 million investment in reforestation and biodiversity

New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia


Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity
News | June 28, 2023

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite


Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction
News | June 28, 2023

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program


USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
Drug Approval | June 27, 2023

USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata

LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12


Ipca Laboratories receives 8 observations from USFDA
Drug Approval | June 24, 2023

Ipca Laboratories receives 8 observations from USFDA

The company will submit its comprehensive response on these observations to the USFDA


Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules
News | June 24, 2023

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India


LVPEI raises awareness on antimicrobial resistance among medical students
News | June 23, 2023

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety